PL-3994

PL-3994 is a synthetic, long-acting, cyclic peptide agonist of natriuretic peptide receptor A (NPR-A), developed by Palatin Technologies. It is designed to mimic the effects of endogenous natriuretic peptides but with improved pharmacokinetic properties, including increased resistance to degradation by neutral endopeptidase and reduced affinity for clearance receptors. Mechanistically, PL-3994 activates NPR-A (also known as atrial natriuretic factor receptor A), leading to increased production of cyclic guanosine monophosphate (cGMP). This results in vasodilation, diuresis, natriuresis, and relaxation of airway smooth muscle. Preclinical studies have shown potent bronchodilator activity and reduction in cardiac hypertrophy and fibrosis. Clinical trials have demonstrated dose-dependent decreases in blood pressure and increases in cGMP levels without serious adverse events. The drug has been investigated for heart failure (including congestive heart failure) and asthma[2][5][6][7][8][9].

Other names

YI2S0GUQ2CYI-2S0GUQ2CYI 2S0GUQ2CUNII-YI2S0GUQ2CUNII-YI-2S0GUQ2CUNII-YI 2S0GUQ2C952295-80-6